Published in J Hepatol on October 14, 2008
Cholangiocarcinoma. Lancet (2014) 4.52
Risk factors for cholangiocarcinoma. Hepatology (2011) 3.27
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol (2009) 2.17
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet (2014) 1.60
Capsaicin treatment attenuates cholangiocarcinoma carcinogenesis. PLoS One (2014) 1.45
Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology (2014) 1.13
Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol (2009) 1.12
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech (2013) 1.01
Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology (2015) 1.00
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci (2012) 0.92
A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer (2011) 0.92
Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis (2014) 0.91
Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol (2015) 0.90
Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS One (2012) 0.90
Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf) (2014) 0.87
Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion (2014) 0.84
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. Dig Dis (2015) 0.83
Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS One (2013) 0.83
Endoscopic and pathological aspects of colitis-associated dysplasia. Nat Rev Gastroenterol Hepatol (2009) 0.83
Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn's disease. Gastroenterol Rep (Oxf) (2014) 0.83
Backwash ileitis and the risk of colon neoplasia in ulcerative colitis patients undergoing restorative proctocolectomy. Dig Dis Sci (2013) 0.82
Advanced therapeutic endoscopist and inflammatory bowel disease: dawn of a new role. World J Gastroenterol (2014) 0.81
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. Tumour Biol (2015) 0.81
A clinical perspective on the role of chronic inflammation in gastrointestinal cancer. Clin Exp Gastroenterol (2014) 0.81
Pancreaticoduodenectomy after liver transplantation in patients with primary sclerosing cholangitis complicated by distal pancreatobiliary malignancy. World J Surg (2010) 0.81
Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist. World J Hepatol (2015) 0.80
Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. HPB (Oxford) (2011) 0.80
Sclerosing Cholangitis: Clinicopathologic Features, Imaging Spectrum, and Systemic Approach to Differential Diagnosis. Korean J Radiol (2016) 0.79
Risk of Colorectal Cancer After Solid Organ Transplantation in the United States. Am J Transplant (2016) 0.79
Sociodemographic trends in the incidence of pancreatic and biliary tract cancer in UK primary care. PLoS One (2014) 0.78
Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies. World J Gastrointest Pharmacol Ther (2016) 0.78
Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective. J Clin Transl Hepatol (2014) 0.77
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology (2017) 0.77
Diabetes mellitus and the risk of cholangiocarcinoma: an updated meta-analysis. Prz Gastroenterol (2015) 0.76
Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol (2014) 0.76
Controversies in the management of primary sclerosing cholangitis. World J Hepatol (2016) 0.76
In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. Dig Dis Sci (2011) 0.76
Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. J Gastrointest Oncol (2015) 0.76
Cholangiocarcinoma and malignant bile duct obstruction: A review of last decades advances in therapeutic endoscopy. World J Gastrointest Endosc (2015) 0.75
Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified? Clin Liver Dis (Hoboken) (2016) 0.75
Primary sclerosing cholangitis and the risk of colon neoplasia in patients with Crohn's colitis. Gastroenterol Rep (Oxf) (2015) 0.75
Prognostic value of neutrophil distribution in cholangiocarcinoma. World J Gastroenterol (2015) 0.75
Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol (2016) 0.75
Estimating a population cumulative incidence under calendar time trends. BMC Med Res Methodol (2017) 0.75
Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. PLoS One (2016) 0.75
Inhibition of JNK signaling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate. Br J Pharmacol (2017) 0.75
Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma? Curr Hepatol Rep (2017) 0.75
Is ileal pouch-anal anastomosis after Whipple procedure doable? Tech Coloproctol (2016) 0.75
Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy. F1000Res (2017) 0.75
The Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single Center Study. J Pediatr Gastroenterol Nutr (2017) 0.75
Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis. World J Gastroenterol (2017) 0.75
Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis. Dig Dis Sci (2016) 0.75
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology (2011) 6.36
Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. JAMA (2012) 3.47
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57
Endoscopic features of sessile serrated adenomas: validation by international experts using high-resolution white-light endoscopy and narrow-band imaging. Gastrointest Endosc (2013) 2.53
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology (2012) 2.39
Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc (2010) 2.38
Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol (2007) 2.26
Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc (2009) 2.23
Safety of endoscopic removal of self-expandable stents after treatment of benign esophageal diseases. Gastrointest Endosc (2013) 2.22
In vitro evaluation of the radial and axial force of self-expanding esophageal stents. Endoscopy (2013) 2.18
Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Gastrointest Endosc (2007) 2.18
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet (2004) 2.06
Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut (2011) 2.03
Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc (2009) 1.97
Neoplasia yield and colonoscopic workload of surveillance regimes for colorectal cancer in colitis patients: a retrospective study comparing the performance of the updated AGA and BSG guidelines. Inflamm Bowel Dis (2013) 1.96
A prospective cohort study evaluating a novel colonoscopy platform featuring full-spectrum endoscopy. Endoscopy (2013) 1.95
Removable self-expanding plastic esophageal stent as a continuous, non-permanent dilator in treating refractory benign esophageal strictures: a prospective two-center study. Am J Gastroenterol (2008) 1.92
Differences in proximal serrated polyp detection among endoscopists are associated with variability in withdrawal time. Gastrointest Endosc (2013) 1.87
Electrocautery therapy for refractory anastomotic strictures of the esophagus. Gastrointest Endosc (2006) 1.76
Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology (2014) 1.75
Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch (2005) 1.74
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut (2011) 1.74
ERCP as an outpatient treatment: a review. Gastrointest Endosc (2008) 1.68
Biomarkers of oxidative stress and risk of developing colorectal cancer: a cohort-nested case-control study in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol (2012) 1.65
Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest Endosc (2004) 1.64
Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2012) 1.64
Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol (2009) 1.60
Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol (2006) 1.60
Is complicated gallstone disease preceded by biliary colic? J Gastrointest Surg (2008) 1.59
Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc (2005) 1.58
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol (2010) 1.58
Plasma alkylresorcinols, biomarkers of whole-grain wheat and rye intake, and incidence of colorectal cancer. J Natl Cancer Inst (2013) 1.57
Ingestion of acid and alkaline agents: outcome and prognostic value of early upper endoscopy. Gastrointest Endosc (2004) 1.57
Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointest Endosc (2008) 1.56
Adenoma detection with cap-assisted colonoscopy versus regular colonoscopy: a randomised controlled trial. Gut (2011) 1.53
Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol (2010) 1.52
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am J Gastroenterol (2008) 1.51
Fully covered self-expandable metal stents (SEMS), partially covered SEMS and self-expandable plastic stents for the treatment of benign esophageal ruptures and anastomotic leaks. BMC Gastroenterol (2012) 1.50
Rising incidence of clinically evident Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol (2007) 1.49
Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc (2010) 1.49
Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol (2007) 1.48
A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc (2009) 1.47
Reduced medication dependency and improved symptoms and quality of life 12 months after enteryx implantation for gastroesophageal reflux. J Clin Gastroenterol (2005) 1.46
No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis (2009) 1.46
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology (2009) 1.45
Nurses working in GI and endoscopic practice: a review. Gastrointest Endosc (2007) 1.42
Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol (2007) 1.42
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology (2013) 1.39
Simulation of a colorectal polypoid lesion--a pilot porcine model. Gastrointest Endosc (2008) 1.39
Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci (2013) 1.38
New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol (2007) 1.34
Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut (2012) 1.32
Location in the right hemi-colon is an independent risk factor for delayed post-polypectomy hemorrhage: a multi-center case-control study. Am J Gastroenterol (2011) 1.32
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis (2013) 1.31
Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer (2011) 1.27
Fruit and vegetable consumption and mortality: European prospective investigation into cancer and nutrition. Am J Epidemiol (2013) 1.22
Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol (2008) 1.21
Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European ppulations. Cancer Epidemiol Biomarkers Prev (2012) 1.20
Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta (2010) 1.20
Plastic or metal stents for benign extrahepatic biliary strictures: a systematic review. BMC Gastroenterol (2009) 1.20
Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol (2011) 1.19
A new esophageal stent design (Niti-S stent) for the prevention of migration: a prospective study in 42 patients. Gastrointest Endosc (2006) 1.18
Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer (2012) 1.18
Endoscopic management of difficult or recurrent esophageal strictures. Am J Gastroenterol (2011) 1.18
Photodynamic therapy for Barrett's esophagus: not yet ready for the premier league of endoscopic interventions. Gastrointest Endosc (2005) 1.17
Esophageal stents for malignant strictures close to the upper esophageal sphincter. Gastrointest Endosc (2007) 1.16
Social inequalities and mortality in Europe--results from a large multi-national cohort. PLoS One (2012) 1.16
Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2006) 1.12
A labelled discrete choice experiment adds realism to the choices presented: preferences for surveillance tests for Barrett esophagus. BMC Med Res Methodol (2009) 1.11
Comparison of standard forward-viewing mode versus ultrawide-viewing mode of a novel colonoscopy platform: a prospective, multicenter study in the detection of simulated polyps in an in vitro colon model (with video). Gastrointest Endosc (2013) 1.10
Conversion of metaplastic Barrett's epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Model Mech (2010) 1.10
A new fully covered metal stent for the treatment of benign and malignant dysphagia: a prospective follow-up study. Gastrointest Endosc (2012) 1.09
A modified self-expanding Niti-S stent for the management of benign hypopharyngeal strictures. Gastrointest Endosc (2007) 1.09
Fruit and vegetable intake and the risk of gastric adenocarcinoma: a reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study after a longer follow-up. Int J Cancer (2012) 1.08
Dynamic contrast-enhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. AJR Am J Roentgenol (2006) 1.08
Slide preparation for single-cell-resolution imaging of fluorescent proteins in their three-dimensional near-native environment. Nat Protoc (2011) 1.07
Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis (2015) 1.04
High acquisition and environmental contamination rates of CC17 ampicillin-resistant Enterococcus faecium in a Dutch hospital. J Antimicrob Chemother (2008) 1.04
Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup. World J Gastroenterol (2012) 1.04
COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol (2007) 1.03
Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. Biochim Biophys Acta (2011) 1.03
Effect of stent size on complications and recurrent dysphagia in patients with esophageal or gastric cardia cancer. Gastrointest Endosc (2007) 1.03
Transluminal endoscopic step-up approach versus minimally invasive surgical step-up approach in patients with infected necrotising pancreatitis (TENSION trial): design and rationale of a randomised controlled multicenter trial [ISRCTN09186711]. BMC Gastroenterol (2013) 1.02
Adult weight change and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Eur J Cancer (2013) 1.00